p130Cas, Crk‐Associated Substrate, Plays Important Roles in Osteoclastic Bone Resorption

p130Cas, Crk‐associated substrate (Cas), is an adaptor/scaffold protein that plays a central role in actin cytoskeletal reorganization. We previously reported that p130Cas is not tyrosine‐phosphorylated in osteoclasts derived from Src‐deficient mice, which are congenitally osteopetrotic, suggesting that p130Cas serves as a downstream molecule of c‐Src and is involved in osteoclastic bone resorption. However, the physiological role of p130Cas in osteoclasts has not yet been confirmed because the p130Cas‐deficient mice displayed embryonic lethality. Osteoclast‐specific p130Cas conditional knockout (p130CasΔOCL–) mice exhibit a high bone mass phenotype caused by defect in multinucleation and cytoskeleton organization causing bone resorption deficiency. Bone marrow cells from p130CasΔOCL– mice were able to differentiate into osteoclasts and wild‐type cells in vitro. However, osteoclasts from p130CasΔOCL– mice failed to form actin rings and resorb pits on dentine slices. Although the initial events of osteoclast attachment, such as β3‐integrin or Src phosphorylation, were intact, the Rac1 activity that organizes the actin cytoskeleton was reduced, and its distribution was disrupted in p130CasΔOCL– osteoclasts. Dedicator of cytokinesis 5 (Dock5), a Rho family guanine nucleotide exchanger, failed to associate with Src or Pyk2 in osteoclasts in the absence of p130Cas. These results strongly indicate that p130Cas plays pivotal roles in osteoclastic bone resorption. © 2013 American Society for Bone and Mineral Research.

[1]  R. Mecham,et al.  Paxillin contracts the osteoclast cytoskeleton , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  H. Takayanagi,et al.  New insights into osteoclastogenic signaling mechanisms , 2012, Trends in Endocrinology & Metabolism.

[3]  David A. Williams,et al.  Rac deletion in osteoclasts causes severe osteopetrosis , 2011, Journal of Cell Science.

[4]  V. Vives,et al.  The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts , 2011, Journal of Bone and Mineral Research.

[5]  G. Karsenty,et al.  Regulation of bone mass by serotonin: molecular biology and therapeutic implications. , 2011, Annual review of medicine.

[6]  H. Kikutani,et al.  Integral roles of a guanine nucleotide exchange factor, FARP2, in osteoclast podosome rearrangements. , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  S. Kato,et al.  The Blimp1–Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis , 2010, The Journal of experimental medicine.

[8]  T. Kodama,et al.  Blimp1-mediated repression of negative regulators is required for osteoclast differentiation , 2010, Proceedings of the National Academy of Sciences.

[9]  K. Aoki,et al.  The pivotal role of the alternative NF‐κB pathway in maintenance of basal bone homeostasis and osteoclastogenesis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  K. Aoki,et al.  Processing of the NF‐κB2 precursor p100 to p52 is critical for RANKL‐induced osteoclast differentiation , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  H. Takayanagi,et al.  Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis , 2009, Nature Medicine.

[12]  B. Mayer,et al.  Phosphorylation of p130Cas initiates Rac activation and membrane ruffling , 2008, BMC Cell Biology.

[13]  Anne J. Ridley,et al.  Mammalian Rho GTPases: new insights into their functions from in vivo studies , 2008, Nature Reviews Molecular Cell Biology.

[14]  C. Marshall,et al.  uPAR promotes formation of the p130Cas–Crk complex to activate Rac through DOCK180 , 2008, The Journal of cell biology.

[15]  P. Chambon,et al.  Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts , 2007, Cell.

[16]  Soo Young Lee,et al.  MafB negatively regulates RANKL-mediated osteoclast differentiation. , 2007, Blood.

[17]  L. Addadi,et al.  Involvement of the Src-cortactin pathway in podosome formation and turnover during polarization of cultured osteoclasts , 2006, Journal of Cell Science.

[18]  Michael P. Sheetz,et al.  Force Sensing by Mechanical Extension of the Src Family Kinase Substrate p130Cas , 2006, Cell.

[19]  M. Hendrix,et al.  Lysyl oxidase regulates actin filament formation through the p130Cas/Crk/DOCK180 signaling complex , 2006, Journal of cellular biochemistry.

[20]  Paola Defilippi,et al.  p130Cas: a versatile scaffold in signaling networks. , 2006, Trends in cell biology.

[21]  S. Ogawa,et al.  Crk-Associated Substrate Lymphocyte Type Is Required for Lymphocyte Trafficking and Marginal Zone B Cell Maintenance1 , 2005, The Journal of Immunology.

[22]  W. Swat,et al.  Vav3 regulates osteoclast function and bone mass , 2005, Nature Medicine.

[23]  C. Der,et al.  GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors , 2005, Nature Reviews Molecular Cell Biology.

[24]  T. Kitamura,et al.  Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. , 2003, Experimental hematology.

[25]  Silvia Bernardini,et al.  Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone Formation , 2000, The Journal of cell biology.

[26]  R. Hynes,et al.  Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. , 2000, The Journal of clinical investigation.

[27]  R. Klemke,et al.  Regulation of Cell Contraction and Membrane Ruffling by Distinct Signals in Migratory Cells , 1999, The Journal of cell biology.

[28]  Michael P. Sheetz,et al.  Selective regulation of integrin–cytoskeleton interactions by the tyrosine kinase Src , 1999, Nature Cell Biology.

[29]  R. Insall,et al.  Signaling to Actin Dynamics , 1999, The Journal of cell biology.

[30]  J. Parsons,et al.  Stable Association of PYK2 and p130Cas in Osteoclasts and Their Co-localization in the Sealing Zone* , 1999, The Journal of Biological Chemistry.

[31]  G. Rodan,et al.  PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. , 1998, The Journal of clinical investigation.

[32]  Kenji Nakamura,et al.  Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas , 1998, Nature Genetics.

[33]  G. Rodan,et al.  Tyrosine Phosphorylation of p130Cas Is Involved in Actin Organization in Osteoclasts* , 1998, The Journal of Biological Chemistry.

[34]  T. Pollard,et al.  Arp2/3 complex from Acanthamoeba binds profilin and cross-links actin filaments. , 1998, Molecular biology of the cell.

[35]  E. Jimi,et al.  Regulation of Osteoclast Function , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  E. Jimi,et al.  Chemical and physical properties of the extracellular matrix are required for the actin ring formation in osteoclasts , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  N. Takahashi,et al.  Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. , 1996, Endocrinology.

[38]  K. Ozawa,et al.  Direct Binding of C-terminal Region of p130 to SH2 and SH3 Domains of Src Kinase (*) , 1996, The Journal of Biological Chemistry.

[39]  N. Udagawa,et al.  A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. , 1995, Bone.

[40]  H. Varmus,et al.  c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. , 1995, Genes & development.

[41]  Sakae Tanaka,et al.  Wortmannin, a specific inhibitor of phosphatidylinositol‐3 kinase, blocks osteoclastic bone resorption , 1995, FEBS letters.

[42]  S. Ogawa,et al.  A novel signaling molecule, p130, forms stable complexes in vivo with v‐Crk and v‐Src in a tyrosine phosphorylation‐dependent manner. , 1994, The EMBO journal.

[43]  M. Horton,et al.  Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins. , 1993, The Journal of biological chemistry.

[44]  T. Yoneda,et al.  Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. , 1992, The Journal of clinical investigation.

[45]  K. Väänänen,et al.  Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  Allan Bradley,et al.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.

[47]  丸山 俊正 Processing of the NF-κB2 precursor p100 to p52 is critical for RANKL-induced osteoclast differentiation , 2011 .

[48]  P. Chambon,et al.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. , 2007, Cell.

[49]  M. Horton,et al.  Biochemical Characterization of Human Osteoclast Integrins , 2001 .

[50]  T. Pollard,et al.  Actin dynamics. , 2001, Journal of cell science.